Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis?  Hans H. Herfarth, MD, PhD  Clinical Gastroenterology and Hepatology  Volume 13, Issue 2, Pages 336-338 (February 2015) DOI: 10.1016/j.cgh.2014.09.045 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Induction dosing of infliximab in severe ulcerative colitis. Most respondents do not use standard dosing in severe ulcerative colitis. The most common approach was to begin with 5 mg/kg, and increase to 10 mg/kg at week 2 if the patient did not respond well, but there was extensive practice variation. IFX, infliximab. Clinical Gastroenterology and Hepatology 2015 13, 336-338DOI: (10.1016/j.cgh.2014.09.045) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Criteria for use of accelerated dosing of infliximab. More than two thirds of respondents used solely clinical criteria to decide which patients should receive accelerated dosing of infliximab, although many included biomarkers such as CRP, erythrocyte sedimentation rate, fecal calprotectin, albumin, and infliximab levels when available. IFX, infliximab. Clinical Gastroenterology and Hepatology 2015 13, 336-338DOI: (10.1016/j.cgh.2014.09.045) Copyright © 2015 AGA Institute Terms and Conditions